At the news
? BULLISHIMPACT 7/10 8-K filed Aug 11, 2026 at 07:11 ET
Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line with consensus of $-0.82. The company highlighted FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, positive Phase 1/2 data for HMB-002 in Von Willebrand Disease, and unveiled a new preclinical program HMB-003. Cash position strengthened to $457.5M post-IPO, providing runway into 2029. The stock will move on pipeline catalysts rather than the pre-revenue financials.
- Net loss of $24.2M ($0.80/share) vs consensus $-0.82, in line
- Cash, cash equivalents, and marketable securities totaled $457.5M as of June 30, 2026, up from $163.5M at March 31, 2026
- FDA endorsed clinical data package for sutacimig as sufficient to proceed to Phase 3 pivotal trial in Glanzmann thrombasthenia; Phase 3 initiation planned 2H 2026
- HMB-002 Phase 1/2 data showed 2.4-fold increase in VWF and FVIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access